Delivery Order SPE2DB20D2104-SPE2DB23FR47B
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $41,086.18 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml pen, with a completion date of January 24, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $3,304.72 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml pen. The contract has a ceiling value of $3,304.72 and a completion date of November 7, 2022. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $4,957.05 firm fixed-price delivery order is for Dupixent 300 mg/2 ml pen 2 ml, a pharmaceutical product. The award has no set-aside designation, indicating full and open competition. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $43,094.75 Firm Fixed Price Delivery Order contract is for the supply of Dupixent 300 mg/2 ml pens, a specialty pharmaceutical product. The contract has a performance period through May 6, 2024 and was awarded on May 3, 2022. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $9,936.76 delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml pen, with a completion date of December 28, 2023. The contract is a firm-fixed-price delivery order and was not set aside for any specific business category. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,389.04 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml syringe and has an ultimate completion date of January 24, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $12,264.35 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml pen, with a final completion date of February 8, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $6,024.73 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml pen, with a completion date of November 8, 2023. The contract is not designated with a set-aside. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $4,957.05 firm fixed-price delivery order is for the pharmaceutical product Dupixent 200 mg/1.14 ml Pen 1.14 ml. The contract has an ultimate completion date of December 6, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
- This is a federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., from the Defense Logistics Agency (DLA). The contract, valued at $5,002.22, is a delivery order for the pharmaceutical product Dupixent 300 mg/2 ml pen. The contract has an ultimate completion date of April 26, 2024 and is a firm fixed-price contract. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FR47BDelivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $3,304.72 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml pen, with a completion date of December 19, 2022. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries. This contract award was made through full and open competition without any set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 12/16/22 |